Categories: All postsCannabis

Green Thumb Industries is cheap compared to other Canadian pot stocks, Echelon says

Ahead of its second quarter financials which are due tomorrow, analyst Russell Stanley of Echelon Wealth Partners is reiterating his “Speculative Buy” rating and 12-month target price of C$20.00 for Green Thumb Industries (Quote, Chart CSE:GTII), representing a projected return of 86 per cent at the time of publication.

Cannabis company Green Thumb owns and operates cannabis cultivation, production and retail businesses in the United States. With interests currently in eight states (representing an aggregate population of 94 million), Green Thumb’s wide coverage sets it apart and gives it “the most diversified platform amongst companies focused on the US market,” says Stanley, in a note to clients on Monday. “And given that each state’s regulations continue to evolve, we believe diversification has real value to investors.”

For GTII’s Q2, the analyst is expecting quarter-over-quarter revenue growth of 19 per cent for $13.0 million (in line with the consensus estimate) along with an EBITDA loss of $3.0 million (versus the consensus loss of $1.6 million. (All figures in US dollars unless noted otherwise.)

Along with the numbers, Stanley says he’ll be looking for an update on Green Thumb’s expansion efforts, particularly with respect to its planned acquisitions in New York and Florida as well as its plans to add more states.

“The EV/C2019E EBITDA multiple discount for US operators relative to Canadian ones has reached 62 per cent (relative to a 38 per cent average),” says Stanley. “This is the highest proportional discount since December 2017 (when it reached 68 per cent) and the highest absolute multiple discount (at 20.5x) in our tracking history.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: gtii
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Magellan Aerospace stock a buy?

Its first quarter results are in the books and Paradigm Capital analyst J Marvin Wolff thinks there is money to… [Read More]

9 hours ago

Phunware is undervalued, Roth says

Ahead of the company's first quarter results, Roth MKM analyst Darren Aftahi thinks there is money to be made on… [Read More]

10 hours ago

Héroux-Devtek is a buy, Desjardins says

Ahead of the company's quarterly results, Desjardins Securities analyst Benoit Poirier likes what he sees from Héroux-Devtek (Héroux-Devtek Stock Quote,… [Read More]

11 hours ago

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

1 day ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

1 day ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

1 day ago